₹1,184.40
Exchange Surveillance
No active ASM or GSM measures on this stock.
Price band — none
Price
Trading Data
range barsReturns
absolute and vs benchmark indexAbout the Company
Cadila Healthcare Ltd operates in areas of active pharmaceutical ingredients (API) to formulations, and animal health products to cosmeceuticals.The company has in-licensing alliances with global multinationals such as Schering AG, Boehringer Ingelheim, Viatris, etc.Their product range includes Formulations that cater to various therapeutic areas such as cardiovascular, gastrointestinal, respiratory, pain management, CNS, anti-infectives, oncology, neurosciences, dermatology and nephrology segments and Consumer product division-brands like Sugar Free, Nutralite and Everyuth.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- HQ
- Ahmedabad, Gujarat
- Chairman
- Pankaj R Patel
- CEO & MD
- Sharvil P Patel
- Registrar
- Link Intime India Pvt. Ltd.
- Exchange
- NSE
- ISIN
- INE010B01027
Institutional Demand
passive ownership through ETFsContext
where this company sitsFrequently Asked
▶What is the share price of Zydus Lifesciences Limited today?
Zydus Lifesciences Limited (ZYDUSLIFE) is trading at ₹1,184.4. The price shown is the latest available from the exchange feed and updates through the trading session.
▶What is ZYDUSLIFE’s P/E ratio versus the sector?
ZYDUSLIFE trades at a P/E of 31.2. Its industry median is shown alongside it in Key Stats, so you can see at a glance whether the stock is priced above or below the businesses it competes with. A lower P/E is not automatically cheaper — it can also reflect slower expected growth.
▶What is ZYDUSLIFE’s dividend yield?
ZYDUSLIFE has a dividend yield of 0.09%, based on dividends declared over the last twelve months against the current price. The full dividend history is on the News & Filings tab.
▶What is ZYDUSLIFE’s 52-week high and low?
ZYDUSLIFE has traded between ₹835.5 and ₹1,232.1 over the past year. The Trading Data block shows where the current price sits inside that band.
▶What is the market capitalisation of Zydus Lifesciences Limited?
Zydus Lifesciences Limited has a market capitalisation of ₹1.14 lakh crore.
▶What is ZYDUSLIFE’s return on equity?
ZYDUSLIFE reports a return on equity of 16.5%. ROE measures profit generated per rupee of shareholder capital, and is most meaningful compared against others in Drug Manufacturers - Specialty & Generic.
▶Who are ZYDUSLIFE’s competitors?
The Peers block on this page lists other Drug Manufacturers - Specialty & Generic companies with their price, P/E and market capitalisation. The Valuation tab compares multiples against the industry median in more depth.
▶What is ZYDUSLIFE’s promoter holding?
Promoters hold 75.02% of ZYDUSLIFE. The Ownership tab shows the full shareholding pattern — promoter, FII, DII and public — and how each has moved across recent quarters.
▶Which indices include ZYDUSLIFE?
Index membership is listed in the Context block on this page, along with the weight ZYDUSLIFE carries in each. That weight is what determines how much passive money tracks the stock.
▶Is Zydus Lifesciences Limited a good buy?
We do not publish buy or sell calls. What this page gives you instead is the evidence: our Value & Investment Index for where the price sits against its own history, the Fundamental Strength Index for the quality of the business, an investment checklist of criteria applied to every stock, and pros and cons generated from ZYDUSLIFE’s own numbers. The judgement is yours.
ZYDUSLIFE at a glance
Zydus Lifesciences Limited operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector. Zydus Lifesciences Limited (ZYDUSLIFE) last traded at ₹1,184.4, giving it a market capitalisation of ₹1.14 lakh crore. The 52-week range is ₹835.5 to ₹1,232.1, and the price is 88% of the way up that range. It trades at a price-to-earnings ratio of 31.2. Promoters hold 75.02% of the company in the latest shareholding filing.
| Market cap | ₹1.14 lakh crore |
|---|---|
| P/E | 31.2 |
| ROE | 16.5% |
| ROCE | 16.6% |